Business Wire

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD ...

The DEPEND study demonstrates that checkpoint inhibitor nivolumab (Opdivo®) works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1 Multikine* is uniquely ...
The American Journal of Managed Care

Higher TMB, PD-L1 Expression Correlate With Shorter Survival in Hematologic Malignancies

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses. Their ...
ascopubs.org

PD-L1 Expression in Biliary Tract Cancer: Comparison Across Antibody Clones and Role as a Predictor of Response to Chemoimmunotherapy: A Meta-Analysis

Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework Observational studies or ...
Cure Today

Lung Cancer PD-L1 Expression Does Not Affect Efficacy of Xalkori

Treatment responses to Xalkori were not affected by PD-L1 expression in patients with advanced non-small cell lung cancer and ROS1 rearrangements. Patients with advanced non-small cell lung cancer ...
MarketWatch

AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth

The MarketWatch News Department was not involved in the creation of this content. Dover, DE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) and its oncology-focused subsidiary ...
News Medical

Immuno-PET imaging for assessing PD-L1 expression in glioblastoma tumors

Patients with Glioblastoma (GBM), a highly aggressive malignant brain tumor, have an extremely poor prognosis due to a lack of viable treatment choices. Since being named the “breakthrough of the year ...
Business Wire

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company’s approach to ...